Page 6 - Generation Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq Four investments already made from BGV IV, with focus on entrepreneurial, therapeutic innovation BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of BGV IV at €140 million ($170 million). BGV IV was oversubscribed, with strong investor demand ...

Share: COPENHAGEN, Denmark, Jan. 7, 2021 /PRNewswire/ -- Novo Ventures, the ventures arm of Novo Holdings, today announces its participation in the BioGeneration Ventures (BGV) oversubscribed fourth fund, 'BGV IV', which has closed at EUR 140M ($170 million).  As one of the most active biotech investors in US and Europe, Novo Ventures' investment strategy is to identify and invest in life science companies developing innovative products with the potential to significantly advance patient care. This investment in BGV IV Fund enhances Novo Ventures' reach into BGV's home market, the Benelux,...